uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City
September 26, 2016 09:18 ET
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 26, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that Matt Kapusta, interim chief...
uniQure Announces Management and Board Changes
September 22, 2016 16:18 ET
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its Board of Directors has...
uniQure Receives NASDAQ Deficiency Letter Related to Board Composition
September 16, 2016 07:13 ET
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 16, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has received a letter from...
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress
August 25, 2016 16:18 ET
|
uniQure
~ Progress Across the Pipeline
~ Additional data on AMT-060 in Hemophilia B Expected Later this Year
~Data from Sanfilippo B and Parkinson's Disease Studies Expected in Q1 2017
~Strong Balance...
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress
August 25, 2016 16:05 ET
|
uniQure
~ Progress Across the Pipeline~ Additional data on AMT-060 in Hemophilia B Expected Later this Year~Data from Sanfilippo B and Parkinson’s Disease Studies Expected in Q1 2017~Strong Balance Sheet to...
uniQure to Present at Upcoming Investor Conferences in September
August 17, 2016 07:12 ET
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that members of its leadership team will...
uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect
July 27, 2016 14:27 ET
|
uniQure
--Data from Low-Dose Cohort of AMT-060 Clinical Trial Continues to Show Durability and Therapeutically Relevant Factor IX (FIX) Activity in Severe, Older Patients with Advanced Joint Disease and...
uniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress
July 11, 2016 13:54 ET
|
uniQure
AMSTERDAM, The Netherlands, July 11, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that updated data from its ongoing Phase I/II clinical study...
uniQure Appoints Jonathan Garen as Chief Business Officer
July 07, 2016 06:43 ET
|
uniQure
AMSTERDAM, the Netherlands, July 7, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer....
uniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications
June 27, 2016 06:30 ET
|
uniQure
AMSTERDAM, the Netherlands, June 27, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Maria E. Cantor as Senior Vice President,...